Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis

Everolimus is an orally administrated mammalian target of rapamycin (mTOR) inhibitor. Several large-scale randomized controlled trials (RCTs) have demonstrated the survival benefits of everolimus at the dose of 10 mg/day for solid cancers. Furthermore, mTOR-inhibitor-based immunosuppression is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Kenya, Petrulionis, Marius, Lin, Shibo, Gao, Chao, Galli, Uwe, Richter, Susanne, Winkler, Susanne, Houben, Philipp, Schultze, Daniel, Hatano, Etsuro, Schemmer, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892390/
https://www.ncbi.nlm.nih.gov/pubmed/24403259
http://dx.doi.org/10.1002/cam4.150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892390/
https://www.ncbi.nlm.nih.gov/pubmed/24403259
http://dx.doi.org/10.1002/cam4.150

Ejemplares similares